MARRONE BIO INNOVATIONS INC: insider trades · United States · SEC (Form 4)

About MARRONE BIO INNOVATIONS INC

Marrone Bio Innovations Inc. (MBII) was a United States-based agricultural biosolutions company focused on biological products for crop protection and plant health. The company was rooted in Davis, California, which fits its innovation profile in agronomy and applied microbiology. For investors in France, Belgium, and Switzerland, it is important to note that MBII was a U.S.-listed company on the NASDAQ market, operating under the SEC disclosure framework and subject to U.S. insider-transaction reporting through Form 4 filings. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001748858/000120919121000351/xslF345X03/doc4.xml?utm_source=openai)) MBII’s core business centered on discovering, developing, and commercializing biological solutions intended to improve crop performance while reducing reliance on conventional chemical inputs. Its portfolio included biofungicides, bioinsecticides, bioherbicides, biostimulants, and seed-treatment solutions. This placed the company in a niche but strategically important segment of agriculture: biological crop inputs. Competitive differentiation in this category typically depends on product efficacy, regulatory acceptance, field performance, and the ability to fit into integrated pest-management programs. MBII’s positioning therefore reflected a science-led business model, competing against both large agrochemical groups and a growing set of specialized bioscience players. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001748858/000120919121000351/xslF345X03/doc4.xml?utm_source=openai)) Geographically, the company was primarily centered in the United States, but its commercial logic was inherently international because biological crop inputs can scale across major farming regions through distributors and strategic partnerships. MBII was not a fully integrated global crop-input giant; rather, it was a smaller, innovation-driven ag-biotech company with meaningful dependence on commercialization execution, market adoption cycles, and capital-market support. That profile often makes such companies more volatile than mature agricultural majors, but also more exposed to upside if biological products gain traction with growers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001748858/000120919121000351/xslF345X03/doc4.xml?utm_source=openai)) A key recent milestone was the company’s change-of-control transaction in 2022, in which it was folded into Bioceres Crop Solutions. That event materially changed MBII’s standalone market profile and means that recent SEC materials, including Form 4 insider filings and merger-related disclosures, are especially relevant for understanding the company’s legacy equity story. In practical terms, MBII should be viewed as a former U.S. NASDAQ-listed biological agriculture innovator, headquartered in California, whose history illustrates the consolidation trend in agri-biotech and biosolutions. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1441693/000120919122042206/xslF345X03/doc4.xml?utm_source=openai))